GO:1904017 cellular response to Thyroglobulin triiodothyronine: Thyroid Hormone Signaling, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904017 describes how a cell changes its state or activity in response to thyroglobulin triiodothyronine, a thyroid hormone-containing protein derivative.
• Thyroglobulin triiodothyronine is generated by proteolysis of thyroglobulin within thyroid follicles, releasing T3 that can act on cells.
• The process is central to thyroid hormone action, affecting gene expression, metabolism, and development.
• Dysregulation is linked to thyroid disorders including hyperthyroidism, hypothyroidism, and goiter [1, 7].
• Key proteins include thyroglobulin (TG), thyroid peroxidase (TPO), TSH receptor (TSHR), and thyroid hormone receptors (THRA/THRB) [4, 5].
• CRISPR-based models (KO, point mutation, knock-in, overexpression) enable causal dissection of this response in thyroid and non-thyroid cells.
Description
The Gene Ontology term GO:1904017, cellular response to Thyroglobulin triiodothyronine, defines the cellular processes triggered by thyroglobulin triiodothyronine, a thyroid hormone derivative. Thyroglobulin triiodothyronine is formed when thyroglobulin, a large glycoprotein stored in thyroid follicles, is proteolyzed to release triiodothyronine (T3). This stimulus can act on cells to alter gene expression, metabolism, and differentiation. Understanding this response is critical because thyroid hormones regulate nearly every tissue, and their imbalance causes widespread pathology. Researchers study GO:1904017 to dissect thyroid hormone signaling, identify therapeutic targets, and model endocrine disorders [2, 4].
cellular response to Thyroglobulin triiodothyronine At A Glance
| GO ID | GO:1904017 |
|---|---|
| GO term | cellular response to Thyroglobulin triiodothyronine |
| Ontology | biological_process |
| Synonym | none |
| Major function | Cellular response to thyroglobulin triiodothyronine stimulus, leading to changes in gene expression, metabolism, and cell activity |
| Related stimulus | Thyroglobulin triiodothyronine, a thyroid hormone-containing protein derivative |
| Key tissues | Thyroid, pituitary, liver, brain, and other thyroid hormone-responsive tissues |
| Associated diseases | Hyperthyroidism, hypothyroidism, goiter, thyroid tumors [1, 4, 7] |
What Is GO:1904017?
GO:1904017 is defined as any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a Thyroglobulin triiodothyronine stimulus. In simpler terms, it is how a cell reacts when it encounters thyroglobulin triiodothyronine, a protein-bound form of the thyroid hormone T3.
Why Is cellular response to Thyroglobulin triiodothyronine Important in Cell Biology?
GO:1904017 is important because it captures a fundamental mechanism of thyroid hormone action at the cellular level. Thyroid hormones control metabolism, growth, and development, and their dysregulation leads to common endocrine disorders such as hyperthyroidism and hypothyroidism. The response to thyroglobulin triiodothyronine specifically reflects the physiological release of T3 from thyroglobulin, a process that is altered in thyroid disease [5, 7]. Studying this term helps researchers understand how cells interpret thyroid hormone signals and how defects contribute to disease, guiding the development of targeted therapies [2, 4].
• Regulates basal metabolic rate and energy homeostasis in multiple tissues.
• Controls gene expression through thyroid hormone receptors (THRA, THRB).
• Essential for normal growth and development, especially of the nervous system.
• Dysregulation causes hyperthyroidism, characterized by weight loss, tachycardia, and heat intolerance.
• Hypothyroidism results from impaired thyroid hormone synthesis or response, including TSH receptor mutations.
• Thyroglobulin levels are used as a biomarker in goiter and thyroid cancer management.
• Autoimmune thyroid disease, such as Graves disease, involves stimulation of the TSH receptor.
• Vitamin D and other factors modulate thyroid tumorigenesis, intersecting with thyroid hormone pathways.
• Xenobiotics can disrupt thyroid follicular cell function, affecting hormone synthesis.
• Animal models, including canine hypothyroidism, provide insights into immune and cellular responses.
What Happens During cellular response to Thyroglobulin triiodothyronine?
Stimulus generation and recognition
In simple terms: The cell first encounters thyroglobulin triiodothyronine, which is released when thyroglobulin is broken down.
Thyroglobulin triiodothyronine is produced by proteolytic cleavage of thyroglobulin within thyroid follicles, liberating T3. This stimulus can act on cells that express thyroid hormone transporters and receptors. The recognition step involves uptake of T3 into the cell and binding to thyroid hormone receptors (THRA/THRB) in the nucleus.
Receptor binding and transcriptional regulation
In simple terms: Once inside, the hormone binds to receptor proteins that switch genes on or off.
T3 binds to thyroid hormone receptors, which are ligand-dependent transcription factors. This binding triggers conformational changes that allow the receptors to regulate target gene expression, often in conjunction with coactivators or corepressors. This step is a hallmark of the cellular response to thyroglobulin triiodothyronine.
Changes in gene expression and cellular activity
In simple terms: The cell then changes which proteins it makes, altering its behavior.
Activated thyroid hormone receptors modulate the transcription of genes involved in metabolism, growth, and differentiation. This leads to changes in enzyme production, secretion, and other cellular activities as defined by GO:1904017. The response can vary by cell type and context.
Feedback and integration with other signals
In simple terms: The cell adjusts its response based on other signals and its own state.
The cellular response to thyroglobulin triiodothyronine is integrated with other signaling pathways, including those involving TSH and growth factors. Feedback mechanisms regulate thyroid hormone synthesis and release, and defects in these loops contribute to disease [4, 5].
Key Genes Involved in GO:1904017 cellular response to Thyroglobulin triiodothyronine
The following genes and proteins are central to the cellular response to thyroglobulin triiodothyronine, based on their roles in thyroid hormone synthesis, transport, receptor signaling, and metabolism.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TG | Thyroglobulin precursor; source of thyroglobulin triiodothyronine | Mutations cause congenital hypothyroidism; biomarker in goiter [4, 7] |
| TPO | Thyroid peroxidase; catalyzes iodination of thyroglobulin | Target in autoimmune thyroid disease; required for hormone synthesis |
| TSHR | TSH receptor; regulates thyroid growth and function | Inactivating mutations cause hypothyroidism; activating mutations cause hyperthyroidism [4, 8] |
| THRA | Thyroid hormone receptor alpha; mediates T3 action | Mutations cause resistance to thyroid hormone; key for gene regulation |
| THRB | Thyroid hormone receptor beta; mediates T3 action | Mutations cause resistance to thyroid hormone; regulates metabolism |
| SLC16A2 | Monocarboxylate transporter 8; T3 transport | Mutations cause Allan-Herndon-Dudley syndrome |
| SLC5A5 | Sodium-iodide symporter; iodide uptake | Defects cause iodide transport defects and hypothyroidism |
| DIO1 | Type 1 deiodinase; converts T4 to T3 | Polymorphisms affect thyroid hormone levels |
| DIO2 | Type 2 deiodinase; local T3 production | Important in brain and pituitary; regulates feedback |
| DIO3 | Type 3 deiodinase; inactivates T3 and T4 | Overexpressed in some tumors; affects hormone availability |
| PAX8 | Transcription factor for thyroid development | Mutations cause congenital hypothyroidism |
| NKX2-1 | Thyroid transcription factor 1 | Regulates thyroglobulin and TPO expression |
| FOXE1 | Thyroid transcription factor 2 | Mutations cause Bamforth-Lazarus syndrome |
| CREB1 | Transcription factor downstream of TSH signaling | Mediates TSH-induced gene expression |
| IGF1 | Growth factor modulating thyroid cell proliferation | Involved in goiter and thyroid tumorigenesis |
| VDR | Vitamin D receptor; modulates thyroid cell differentiation | Linked to thyroid tumorigenesis and development |
| CD40 | Immune costimulatory molecule | Implicated in autoimmune thyroid disease |
| HLA-DR | Major histocompatibility complex class II | Associated with Graves disease and autoimmune hypothyroidism [3, 8] |
How Is cellular response to Thyroglobulin triiodothyronine Regulated?
The cellular response to thyroglobulin triiodothyronine is regulated at multiple levels. Thyroid hormone synthesis and release are controlled by TSH via the TSHR, which activates cAMP signaling and downstream transcription factors [4, 5]. Deiodinases (DIO1, DIO2, DIO3) modulate local T3 availability, thereby influencing the strength of the response. Thyroid hormone receptors (THRA, THRB) and their coregulators determine which genes are activated or repressed. Additionally, immune and environmental factors, such as xenobiotics, can disrupt thyroid follicular cell function and hormone production. In disease states like Graves disease, autoantibodies stimulate the TSHR, mimicking TSH and altering the cellular response.
cellular response to Thyroglobulin triiodothyronine and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TSHR | Congenital hypothyroidism with TSH resistance | Knock-in of inactivating mutation in TSHR |
| TG | Goiter and thyroid dyshormonogenesis | Knockout of TG in thyroid cell lines |
| THRB | Resistance to thyroid hormone | Point mutation in THRB ligand-binding domain |
| VDR | Thyroid tumorigenesis | Overexpression or knockout of VDR in thyroid cancer cells |
| HLA-DR | Autoimmune thyroid disease | Knock-in of risk alleles in immune cell models [3, 8] |
Hyperthyroidism and Graves disease
Hyperthyroidism is characterized by excessive thyroid hormone action, leading to weight loss, tachycardia, and heat intolerance. In Graves disease, autoantibodies activate the TSH receptor, driving overproduction of thyroid hormones and thyroglobulin triiodothyronine. This results in sustained cellular responses in multiple tissues. HIV-infected patients on antiretroviral therapy may present with distinct characteristics of Graves disease.
Hypothyroidism and TSH receptor defects
Hypothyroidism results from insufficient thyroid hormone production or action. Inactivating mutations in the TSH receptor gene can cause congenital hypothyroidism with absent circulating thyroglobulin, highlighting the importance of TSHR signaling for thyroglobulin synthesis and hormone release. Canine hypothyroidism models show humoral and cellular immune responses that mirror aspects of human disease.
Goiter and thyroid tumors
Nontoxic goiter is associated with altered thyroglobulin levels, and serum thyroglobulin concentration can predict relapse after surgery. Thyroid tumorigenesis involves dysregulation of thyroid hormone pathways, with vitamin D and its receptor (VDR) playing modulatory roles. Xenobiotics can also affect thyroid follicular cells, potentially contributing to goiter and neoplasia.
From cellular response to Thyroglobulin triiodothyronine-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TSHR mutation impair thyroglobulin triiodothyronine response? | Point mutation knock-in in thyroid cells |
| What is the role of TG in hormone release? | TG knockout in thyroid follicular cells |
| How does THRB mutation affect gene regulation? | Knock-in of mutant THRB in hepatocytes |
| Can overexpression of DIO2 enhance local T3 production? | Overexpression of DIO2 in neuronal cells |
| What genes are essential for thyroid hormone transport? | Knockout of SLC16A2 in astrocytes |
| How does VDR modulate thyroid tumor growth? | VDR knockout in thyroid cancer xenografts |
How to Study the cellular response to Thyroglobulin triiodothyronine Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify T3-responsive genes |
| Proteomics | Protein abundance and modifications | Detect post-transcriptional effects |
| Metabolomics | Metabolite levels | Assess metabolic reprogramming |
| Reporter assays | Thyroid hormone receptor activity | Screen for agonists/antagonists |
| CRISPR knockout screen | Gene essentiality for the response | Discover novel regulators |
| ChIP-seq | Receptor binding sites | Map THRA/THRB genomic targets |
| Immunofluorescence | Protein localization | Visualize thyroglobulin trafficking |
| ELISA | Thyroglobulin or T3 levels | Measure hormone secretion |
Transcriptomics and RNA-seq
RNA sequencing can identify global changes in gene expression following thyroglobulin triiodothyronine stimulation, revealing target genes and pathways. This method is useful for comparing wild-type and mutant cells to dissect the response.
Proteomics and metabolomics
Proteomic profiling can detect changes in protein abundance and post-translational modifications, while metabolomics reveals shifts in metabolic pathways controlled by thyroid hormones. These approaches complement transcriptomic data.
Imaging and reporter assays
Fluorescent or luminescent reporters can monitor thyroid hormone receptor activity in live cells. Imaging of thyroid follicles can visualize thyroglobulin processing and hormone release.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify genes that modify the cellular response to thyroglobulin triiodothyronine, uncovering novel regulators and potential drug targets.
How CRISPR Can Be Used to Study GO:1904017 cellular response to Thyroglobulin triiodothyronine
Knockout
CRISPR knockout of genes such as TG, TSHR, or THRB can abolish or reduce the cellular response to thyroglobulin triiodothyronine, providing causal evidence for their roles [4, 7]. Knockout cell lines are valuable for studying loss-of-function phenotypes.
Point Mutation
Introducing specific point mutations (e.g., in TSHR or THRB) via CRISPR base editing or homology-directed repair can model human disease variants and reveal how single amino acid changes alter the response [4, 2].
Knock-in
Knock-in of tagged or reporter alleles (e.g., GFP-TG) allows real-time tracking of thyroglobulin processing and hormone release in live cells. Knock-in of disease-associated alleles can create isogenic models.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can increase the levels of key genes like DIO2 or VDR, enabling gain-of-function studies to test their impact on the cellular response [2, 6].
How EDITGENE Supports cellular response to Thyroglobulin triiodothyronine Research
Researchers studying cellular response to Thyroglobulin triiodothyronine-related genes often need to determine whether a candidate gene is causally involved in the response or merely correlated. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for cellular response to Thyroglobulin triiodothyronine research.
Frequently Asked Questions About cellular response to Thyroglobulin triiodothyronine
What is GO:1904017?
GO:1904017 is the Gene Ontology term for cellular response to Thyroglobulin triiodothyronine, describing how a cell changes its state or activity in response to this thyroid hormone derivative.
What is thyroglobulin triiodothyronine?
Thyroglobulin triiodothyronine is a form of triiodothyronine (T3) that is bound within or derived from thyroglobulin, a large protein stored in the thyroid gland.
What genes are involved in cellular response to Thyroglobulin triiodothyronine?
Key genes include TG, TPO, TSHR, THRA, THRB, SLC16A2, DIO1, DIO2, DIO3, PAX8, NKX2-1, and FOXE1, among others [2, 4, 5].
How is the cellular response to Thyroglobulin triiodothyronine regulated?
It is regulated by TSH via the TSH receptor, deiodinases that control local T3 levels, thyroid hormone receptors, and coregulators [2, 4].
What diseases are associated with defects in this response?
Hyperthyroidism, hypothyroidism, goiter, and thyroid tumors are associated with dysregulation of this response [1, 4, 7].
How can CRISPR be used to study GO:1904017?
CRISPR knockout, point mutation, knock-in, and overexpression can create isogenic models to test the causal role of specific genes in the response [2, 4].
What methods are used to study cellular response to Thyroglobulin triiodothyronine?
Common methods include RNA-seq, proteomics, metabolomics, reporter assays, ChIP-seq, and CRISPR screens.
What is the role of TSHR in this process?
TSHR mediates TSH signaling, which stimulates thyroid hormone synthesis and release; inactivating mutations cause hypothyroidism.
Can thyroglobulin levels predict goiter relapse?
Serum thyroglobulin concentration in nontoxic goiter can predict the risk of relapse after surgery.
What cell models are available for studying this response?
Thyroid cell lines, hepatocytes, neuronal cells, and immune cells can be engineered using CRISPR to model the response [2, 6].
Conclusion
GO:1904017, cellular response to Thyroglobulin triiodothyronine, represents a critical intersection of endocrine signaling and cellular adaptation. Understanding this process illuminates thyroid hormone action in health and disease, from hyperthyroidism to thyroid cancer [1, 2, 7]. CRISPR-based models offer powerful tools to dissect the underlying mechanisms and identify therapeutic targets. EDITGENE's comprehensive services support researchers in generating precise cell models to advance this field.
References
- 1. Mathew P et al.. 2026. Hyperthyroidism (Nursing).. PMID: 33760541
- 2. Contreras-Jurado C. 2025. Thyroid Hormones and Co-workers: An Overview.. Methods Mol Biol 2876:3-16 PMID: 39579305
- 3. Miller J et al.. 2015. Humoral and Cellular Immune Response in Canine Hypothyroidism.. J Comp Pathol 153(1):28-37 PMID: 25958183
- 4. Tonacchera M et al.. 2000. Congenital hypothyroidism with impaired thyroid response to thyrotropin (TSH) and absent circulating thyroglobulin: evidence for a new inactivating mutation of the TSH receptor gene.. J Clin Endocrinol Metab 85(3):1001-8 PMID: 10720030
- 5. Capen CC et al.. 1989. The effects of xenobiotics on the structure and function of thyroid follicular and C-cells.. Toxicol Pathol 17(2):266-93 PMID: 2675279
- 6. Clinckspoor I et al.. 2013. Vitamin D in thyroid tumorigenesis and development.. Prog Histochem Cytochem 48(2):65-98 PMID: 23890557
- 7. Feldt-Rasmussen U et al.. 1986. Serum thyroglobulin concentration in nontoxic goiter and response to surgery with special reference to risk of goiter relapse.. World J Surg 10(4):566-71 PMID: 3092474
- 8. Jariyawattanarat V et al.. 2020. CHARACTERISTICS OF GRAVES DISEASE IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY.. Endocr Pract 26(6):612-618 PMID: 31968184
